SET and MYND Domain Containing Protein 3 in Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2017 Jan 27

PMID 28123630

Citations 31

Authors

Lei Huang

A-Man Xu

Affiliations

Soon will be listed here.

Abstract

Lysine methylation plays a vital role in histone modification. Deregulations of lysine methyltransferases and demethylases have been frequently observed in human cancers. The SET and MYND domain containing protein 3 (SMYD3) is a novel histone lysine methyltransferase and it functions by regulating chromatin during the development of myocardial and skeletal muscle. It has been recently unveiled to play significant roles in human cancer genesis and progression via regulating various key cancer-associated genes and pathways and promoting cell proliferation and migration. Upregulation of SMYD3 expression is present in multiple cancer types, suggesting it as a potential prognostic marker. Herein the structure, substrates and targets of SMYD3, and its effects on initiation, invasion and metastasis of diverse tumors (, esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, breast cancer, prostate cancer, and leukemia) are systematically reviewed, providing clues for the development of novel SMYD3-specific personalized anti-cancer therapy. SMYD3 inhibitors (, BCI-121 and novobiocin) could hopefully fight against tumors with efficacy.

Citing Articles

From microscopes to molecules: The evolution of prostate cancer diagnostics.

Tao J, Bian X, Zhou J, Zhang M Cytojournal. 2024; 21:29.

PMID: 39391208 PMC: 11464998. DOI: 10.25259/Cytojournal_36_2024.

Epigenetic (De)regulation in Prostate Cancer.

Xu C, Zhao S, Cai L Cancer Treat Res. 2023; 190:321-360.

PMID: 38113006 PMC: 11421856. DOI: 10.1007/978-3-031-45654-1_10.

The epigenetic function of androgen receptor in prostate cancer progression.

Sawada T, Kanemoto Y, Kurokawa T, Kato S Front Cell Dev Biol. 2023; 11:1083486.

PMID: 37025180 PMC: 10070878. DOI: 10.3389/fcell.2023.1083486.

SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.

Wang P, Zhao L, Rui Y, Ding Y Cancer Gene Ther. 2022; 30(4):575-581.

PMID: 36127410 DOI: 10.1038/s41417-022-00535-5.

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer.

Wu Y, Zhang X, Li L, Yang W, Yan Z, Gu C Onco Targets Ther. 2022; 15:973-979.

PMID: 36118677 PMC: 9480580. DOI: 10.2147/OTT.S375643.

References

Liu C, Wang C, Wang K, Liu L, Shen Q, Yan K . SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J Natl Cancer Inst. 2013; 105(22):1719-28. DOI: 10.1093/jnci/djt304. View

Chen L, Xu J, Yang Z, Wang G . Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol. 2007; 13(43):5718-24. PMC: 4171257. DOI: 10.3748/wjg.v13.i43.5718. View

Helin K, Dhanak D . Chromatin proteins and modifications as drug targets. Nature. 2013; 502(7472):480-8. DOI: 10.1038/nature12751. View

Ren T, Wang J, He Y, Xu C, Wang S, Xi T . Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells. Med Oncol. 2010; 28 Suppl 1:S91-8. DOI: 10.1007/s12032-010-9718-6. View

Liu Y, Deng J, Luo X, Pan Y, Zhang L, Zhang R . Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Med Oncol. 2014; 32(1):404. DOI: 10.1007/s12032-014-0404-y. View

Liu C, Fang X, Ge Z, Jalink M, Kyo S, Bjorkholm M . The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res. 2007; 67(6):2626-31. DOI: 10.1158/0008-5472.CAN-06-4126. View

Liu Y, Liu H, Luo X, Deng J, Pan Y, Liang H . Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. Tumour Biol. 2015; 36(6):4377-86. DOI: 10.1007/s13277-015-3077-z. View

Dai B, Wan W, Zhang P, Zhang Y, Pan C, Meng G . SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity. Oncol Rep. 2015; 34(5):2722-30. DOI: 10.3892/or.2015.4239. View

Huang L, Xu A, Liu W . Transglutaminase 2 in cancer. Am J Cancer Res. 2015; 5(9):2756-76. PMC: 4633903. View

10.

Chi P, Allis C, Wang G . Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10(7):457-69. PMC: 3262678. DOI: 10.1038/nrc2876. View

11.

Zeng B, Li Z, Chen R, Guo N, Zhou J, Zhou Q . Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Lett. 2012; 586(19):3271-8. DOI: 10.1016/j.febslet.2012.06.049. View

12.

Fu W, Liu N, Qiao Q, Wang M, Min J, Zhu B . Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase. J Biol Chem. 2016; 291(17):9173-80. PMC: 4861483. DOI: 10.1074/jbc.M115.709832. View

13.

Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva F, Li M . SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6(8):731-40. DOI: 10.1038/ncb1151. View

14.

Kunizaki M, Hamamoto R, Silva F, Yamaguchi K, Nagayasu T, Shibuya M . The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 2007; 67(22):10759-65. DOI: 10.1158/0008-5472.CAN-07-1132. View

15.

Luo X, Ding Y, Zhou Q, Ye L, Wang S, Xi T . SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. J Biosci Bioeng. 2007; 103(5):444-50. DOI: 10.1263/jbb.103.444. View

16.

Wang S, Luo X, Shen J, Zou J, Lu Y, Xi T . Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro. BMB Rep. 2008; 41(4):294-9. DOI: 10.5483/bmbrep.2008.41.4.294. View

17.

Zhu Y, Zhu M, Zhang X, Xu X, Wu Z, Liao L . SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Hum Pathol. 2016; 52:153-63. DOI: 10.1016/j.humpath.2016.01.012. View

18.

Van Aller G, Graves A, Elkins P, Bonnette W, McDevitt P, Zappacosta F . Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016; 24(5):774-781. DOI: 10.1016/j.str.2016.03.010. View

19.

Hamamoto R, Saloura V, Nakamura Y . Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer. 2015; 15(2):110-24. DOI: 10.1038/nrc3884. View

20.

Mazur P, Reynoird N, Khatri P, Jansen P, Wilkinson A, Liu S . SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014; 510(7504):283-7. PMC: 4122675. DOI: 10.1038/nature13320. View